SRP3160
sRank レセプター ヒト
recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
別名:
ODAR (骨芽細胞分化および活性化レセプター), TNFRSF11A, TRANCE レセプター
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
NACRES:
NA.32
UNSPSC Code:
12352200
Form:
lyophilized
Assay:
≥98% (HPLC), ≥98% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
19.3 kDa
biological source
human
recombinant
expressed in E. coli
assay
≥98% (HPLC), ≥98% (SDS-PAGE)
form
lyophilized
potency
30-50 ng/mL ED50
mol wt
19.3 kDa
packaging
pkg of 100 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
color
white
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... TNFRSF11A(8792)
General description
Soluble receptor activator of nuclear factor-κB (sRANK) also known as TNF receptor superfamily member 11a (TNFRSF11A), is encoded by the gene mapped to human chromosome 18. The encoded protein belongs to the tumor necrosis factor (TNF) receptor superfamily. RANK is widely expressed in variety of tissues, including skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoclast, mammary gland epithelial cells, prostate and pancreas. Recombinant human sRANK receptor is a 19.3kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (175 amino acid residues).
Biochem/physiol Actions
Soluble receptor activator of nuclear factor-κB (sRANK) plays a vital role in bone remodeling and fracture repair. Alterations in the RANK signaling increase the risk of susceptibility to expansile osteolysis and Paget disease of bone (PDB2). In addition, mutation of the gene coding for RANK/RANKL/OPG has also been observed in various skeletal disorders such as osteoporosis, glucocorticoid-induced bone loss, multiple myeloma, and rheumatoid arthritis. Binding of RANKL to its receptor RANK triggers the formation and differentiation of osteoclasts with the help of various transcription factors involved in modulation of osteoclastogenesis. RANK/RANKL/OPG might act as a potent therapeutic target for bone diseases.
Physical form
凍結乾燥品(10 mMリン酸ナトリウム、pH 7.2)。
Preparation Note
バイアルは、開封前に遠心してください。0.1～1.0 mg/mLの濃度となるよう水で再構成してください。ボルテックスは行わないでください。この溶液は2～8°Cで1週間まで保存できます。長期保存の際は、キャリアタンパク質(0.1% BSAなど)を含有するバッファーで希釈し、1回使用量ごとに分けて-20～-80°Cで保存することをお勧めします。
Other Notes
MQIAPPCTSE KHYEHLGRCC NKCEPGKYMS SKCTTTSDSV CLPCGPDEYL DSWNEEDKCL LHKVCDTGKA LVAVVAGNST TPRRCACTAG YHWSQDCECC RRNTECAPGL GAQHPLQLNK DTVCKPCLAG YFSDAFSSTD KCRPWTNCTF LGKRVEHHGT EKSDAVCSSS LPARK
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
SRP3160-100UG:
jan
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
Hughes AE
Nature Genetics, 24(1), 45-48 (2000)
Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.
Colombini A
International Orthopaedics, 35(5), 777-782 (2011)
RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T
Trends in Molecular Medicine, 12(1), 17-25 (2006)